Related Experiment Video
Updated: Feb 7, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Ibrutinib-related atrial fibrillation: Therapeutic challenges
Chris J Kapelios1, Maria S Bonou1, Panagiotis Diamantopoulos2
11 Department of Cardiology, Laiko General Hospital, Athens, Greece.
Insights
Ibrutinib treatment for lymphohyperplastic diseases can cause atrial fibrillation. Intravenous amiodarone successfully restored sinus rhythm in a challenging case, highlighting therapeutic options.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Ibrutinib is a Bruton's tyrosine kinase inhibitor used for lymphoproliferative disorders.
- Ibrutinib therapy is linked to an increased risk of atrial fibrillation (AF).
- Managing new-onset AF in patients on ibrutinib presents therapeutic challenges due to contraindications for certain antiarrhythmics and anticoagulation limitations.
Purpose of the Study:
- To describe the management of a patient with ibrutinib-associated new-onset atrial fibrillation.
- To discuss the challenges in rhythm control and anticoagulation for this patient population.
Main Methods:
- Case report of a 55-year-old patient on ibrutinib presenting with new-onset AF and borderline blood pressure.
- Attempted rhythm control with intravenous amiodarone when first-line therapies (electrical cardioversion, ablation) were not feasible.
Main Results:
- Intravenous amiodarone administration led to prompt restoration of sinus rhythm.
- The patient's borderline arterial pressure was managed during treatment.
Conclusions:
- Rhythm control with intravenous amiodarone can be effective for ibrutinib-associated AF when first-line options are contraindicated.
- Careful consideration of anticoagulation and rhythm control strategies is crucial in these complex patients.
Abstract:
Ibrutinib is a drug used in several lymphohyperplastic diseases. Its use is associated with an increased risk of atrial fibrillation. New-onset atrial fibrillation in this setting is a true challenge as several antiarrhythmic drugs are not indicated and long-term anticoagulation has several limitations. Herein, we describe our experience in treating a 55-year-old patient receiving ibrutinib who presented with new-onset atrial fibrillation and borderline arterial pressure. Since first-line therapies, electrical cardioversion and ablation, could not be performed, rhythm control with intravenous administration of amiodarone was attempted and led to prompt sinus rhythm restoration. We discuss the therapeutic challenges related to sinus rhythm restoration and anticoagulation in this group of atrial fibrillation patients.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...

